• Publications
  • Influence
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results
TLDR
The combined clinimetric results of this study support the validity of the MDS‐UPDRS for rating PD.
Second consensus statement on the diagnosis of multiple system atrophy
TLDR
New criteria for diagnosis of multiple system atrophy have simplified the previous criteria, have incorporated current knowledge, and are expected to enhance future assessments of the disease.
Clinical diagnostic criteria for dementia associated with Parkinson's disease
TLDR
Clinical diagnostic criteria for probable and possible PD‐D are proposed, characterized by impairment in attention, memory, executive and visuo‐spatial functions, behavioral symptoms such as affective changes, hallucinations, and apathy are frequent.
MDS clinical diagnostic criteria for Parkinson's disease
TLDR
The Movement Disorder Society PD Criteria retain motor parkinsonism as the core feature of the disease, defined as bradykinesia plus rest tremor or rigidity, and two levels of certainty are delineated: clinically established PD and probable PD.
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan
TLDR
The MDS‐UPDRS retains the UPDRS structure of four parts with a total summed score, but the parts have been modified to provide a section that integrates nonmotor elements of PD: I, Nonmotor Experiences of Daily Living; II, Motor Exper experiences of daily Living; III, Motor Examination; and IV, Motor Complications.
Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease
TLDR
The Movement Disorder Society Task Force for Rating Scales for Parkinson's disease (PD) prepared a critique of the Hoehn and Yahr scale, which recommends that it be used in its original form for demographic presentation of patient groups and in research settings, the HY scale is useful primarily for defining inclusion/exclusion criteria.
A randomized trial of deep-brain stimulation for Parkinson's disease.
TLDR
In this six-month study of patients under 75 years of age with severe motor complications of Parkinson's disease, neurostimulation of the subthalamic nucleus was more effective than medical management alone.
The Parkinson Progression Marker Initiative (PPMI)
Depression rating scales in Parkinson's disease: Critique and recommendations
TLDR
A systematic literature review was conducted to explore the use of depression scales in PD and determine which scales should be selected, and found that the complex and time‐consuming task of developing a new scale to measure depression specifically for patients with PD is currently not warranted.
Rivastigmine for dementia associated with Parkinson's disease.
TLDR
Rivastigmine was associated with moderate improvements in dementia associated with Parkinson's disease but also with higher rates of nausea, vomiting, and tremor; however, the differences between these two groups were moderate and similar to those reported in trials of rivastIGmine for Alzheimer's disease.
...
...